Immunophotonics is a clinical-stage biotech pioneering Interventional Immuno-Oncology: its lead candidate IP-001, a proprietary glycan polymer, is injected after routine tumor-ablation procedures to prolong the availability of liberated tumor antigens and stimulate a systemic immune response against residual cancer cells. The company is advancing IP-001 through Phase 2 programs across multiple solid tumor indications, including colorectal, lung, liver and pancreatic cancers. Founded in 2012, it is headquartered in St. Louis, Missouri, with a European headquarters in Bern, Switzerland.
1
Round
1
Industry
5
Tags
Sep 1, 2026
Latest raise
Funding activity · 1 round
Sep 1, 2026
$10M
Series C+
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
